Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors.

Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D, Petersén Å.

Eur J Neurosci. 2012 Sep;36(6):2789-800. doi: 10.1111/j.1460-9568.2012.08193.x. Epub 2012 Jun 25.

PMID:
22731249
2.

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA.

J Neurosci. 2009 Sep 16;29(37):11550-9. doi: 10.1523/JNEUROSCI.3307-09.2009.

4.

Recombinant Adeno Associated Viral (AAV) vector type 9 delivery of Ex1-Q138-mutant huntingtin in the rat striatum as a short-time model for in vivo studies in drug discovery.

Ceccarelli I, Fiengo P, Remelli R, Miragliotta V, Rossini L, Biotti I, Cappelli A, Petricca L, La Rosa S, Caricasole A, Pollio G, Scali C.

Neurobiol Dis. 2016 Feb;86:41-51. doi: 10.1016/j.nbd.2015.11.019. Epub 2015 Nov 25.

PMID:
26626080
5.

Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain.

Kornum BR, Stott SR, Mattsson B, Wisman L, Ettrup A, Hermening S, Knudsen GM, Kirik D.

Exp Neurol. 2010 Mar;222(1):70-85. doi: 10.1016/j.expneurol.2009.12.009. Epub 2009 Dec 16.

PMID:
20025873
7.

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.

Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, Rey M, Lubelski J, Evers MM, van Deventer SJ, Petry H, Déglon N, Konstantinova P.

Gene Ther. 2017 Oct;24(10):630-639. doi: 10.1038/gt.2017.71. Epub 2017 Aug 3.

8.

Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment.

Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD, Aebischer P, Déglon N.

Neurobiol Dis. 2005 Dec;20(3):785-98. Epub 2005 Jul 11.

PMID:
16006135
9.

Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.

Gharami K, Xie Y, An JJ, Tonegawa S, Xu B.

J Neurochem. 2008 Apr;105(2):369-79. Epub 2007 Dec 12.

10.

Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF.

J Comp Neurol. 2003 Oct 6;465(1):11-26.

PMID:
12926013
11.

Diminished activity-dependent brain-derived neurotrophic factor expression underlies cortical neuron microcircuit hypoconnectivity resulting from exposure to mutant huntingtin fragments.

Gambazzi L, Gokce O, Seredenina T, Katsyuba E, Runne H, Markram H, Giugliano M, Luthi-Carter R.

J Pharmacol Exp Ther. 2010 Oct;335(1):13-22. doi: 10.1124/jpet.110.167551. Epub 2010 Jul 12.

PMID:
20624994
12.

Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Menalled LB, Sison JD, Wu Y, Olivieri M, Li XJ, Li H, Zeitlin S, Chesselet MF.

J Neurosci. 2002 Sep 15;22(18):8266-76.

13.

Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.

Dong X, Zong S, Witting A, Lindenberg KS, Kochanek S, Huang B.

J Gene Med. 2012 Jul;14(7):468-81. doi: 10.1002/jgm.2641.

PMID:
22700462
14.

AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D.

Mol Ther. 2008 May;16(5):947-56. doi: 10.1038/mt.2008.50. Epub 2008 Mar 25.

15.

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum.

Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J, Weatherspoon MR, Blum JL, Burright EN, Zhang Z, Kaemmerer WF.

Brain. 2012 Apr;135(Pt 4):1197-209. doi: 10.1093/brain/awr333. Epub 2012 Jan 16.

16.

Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Reddy PH, Charles V, Williams M, Miller G, Whetsell WO Jr, Tagle DA.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):1035-45.

17.

Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.

Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR.

Hum Mol Genet. 2005 May 15;14(10):1379-92. Epub 2005 Apr 13.

PMID:
15829505
18.

Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.

Tanaka Y, Igarashi S, Nakamura M, Gafni J, Torcassi C, Schilling G, Crippen D, Wood JD, Sawa A, Jenkins NA, Copeland NG, Borchelt DR, Ross CA, Ellerby LM.

Neurobiol Dis. 2006 Feb;21(2):381-91. Epub 2005 Sep 16.

PMID:
16150600
19.
20.

Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL.

Mol Ther. 2014 Apr;22(4):797-810. doi: 10.1038/mt.2013.289. Epub 2014 Jan 6.

Supplemental Content

Support Center